Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
Ofloxacin Ophthalmic Solution USP 0.3% is indicated for treatment of eye infections caused during the conditions of conjunctivitis and corneal ulcers
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac Tablets of Eli Lilly
The Product is expected to be the first generic approval on the market
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ II, India
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty
The product will be launched in March 2024
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
Subscribe To Our Newsletter & Stay Updated
